Characterization of hepatic DNA damage induced in rats by the pyrrolizidine alkaloid monocrotaline.

Hepatic DNA damage induced by the pyrrolizidine alkaloid monocrotaline was evaluated following i.p. administration to adult male Sprague-Dawley rats. Animals were treated with various doses ranging upward from 5 mg/kg, and hepatic nuclei were isolated 4 hr later. Hepatic nuclei were used as the DNA source in all experiments. DNA damage was characterized by the alkaline elution technique. A mixture of DNA-DNA interstrand cross-links and DNA-protein cross-links was induced. Following an injection of monocrotaline, 30 mg/kg i.p., DNA-DNA interstrand cross-linking reached a maximum within 12 hr or less and thereafter decreased over a protracted period of time. By 96 hr postadministration, the calculated cross-linking factor was no longer statistically different from zero. No evidence for the induction of DNA single-strand breaks was observed, although the presence of small numbers of DNA single-strand breaks could have been masked by the overwhelming predominance of DNA cross-links. These DNA cross-links may be related to the hepatocarcinogenic, hepatotoxic, and/or antimitotic effects of monocrotaline.

Low affinity binding of taurine to phospholiposomes and cardiac sarcolemma.

A sarcolemma-enriched membrane fraction was prepared from the hearts of Sprague-Dawley rats and its ability to bind taurine (0.5-150 mM) was measured. In the absence of cations, the sarcolemma bound a maximum of 661 nmol taurine/mg protein, with a dissociation constant of 19.2 mM and a Hill coefficient of 1.9, indicating positive cooperativity. Scatchard analysis of taurine binding to sarcolemma gave a bell-shaped curve. Neither beta-alanine nor guanidinoethane sulfonate, inhibitors of taurine transport, affected the degree of taurine binding to sarcolemma. However, hypotaurine was an effective antagonist. Equimolar concentrations of Ca2+, Na+ or K+ also reduced taurine binding. Heterogeneous phospholipid vesicles of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine (18:19:2:1) also bound taurine with positive cooperativity, yielding a bell-shaped Scatchard curve. The affinity of taurine for these mixed phospholipid vesicles was enhanced by the inclusion of cholesterol (50%). Taurine associated in a maximum ratio of 1:1 with homogeneous vesicles of phosphatidylcholine or phosphatidylserine. Vesicles of phosphatidylethanolamine bound taurine in a maximum ratio of 2:1, whereas those of phosphatidylinositol bound insignificant amounts of taurine. These studies demonstrate a low affinity binding to sarcolemma of taurine at concentrations normally present in rat heart. Similar levels of binding were observed in phospholipid vesicles, suggesting that the interaction of taurine with biological membranes involves phospholipids.

Activation and pulmonary toxicity of pyrrolizidine alkaloids.

Pyrrolizidine alkaloids unsaturated in the 1,2 position are hepatotoxins. Certain of them, such as monocrotaline, are also pneumotoxins, producing pulmonary arterial hypertension and right ventricular hypertrophy as a delayed response two weeks after administration. Pneumotoxicity is the result of hepatic metabolism, the lung itself being unable to bioactivate pyrrolizidine alkaloids. The changes produced in the lung following exposure to pneumotoxic pyrrolizidine alkaloids are reviewed, together with the factors and interventions which modify or influence these changes. In the main, the earliest changes are seen in vascular smooth muscle and in the interactions between the smooth muscle and the endothelium. The search to identify the pneumotoxic metabolite is reviewed. It is generally accepted that pyrroles, or dehydroalkaloids, are responsible for the toxicity of pyrrolizidines. However, the primary pyrroles are intensely reactive, hydrolyzing and polymerizing within seconds in aqueous solution. Evidence for and against the pneumotoxin being a primary pyrrole or a stabilized secondary conversion product of a primary pyrrole is discussed.

Higher susceptibility of taurine-deficient rats to seizures induced by 4-aminopyridine.

The susceptibility of rats made deficient of taurine by treatment with guanidinoethane sulfonate (GES), to seizures induced by 4-aminopyridine was examined. Guanidinoethane sulfonate, at a concentration of 1% was administered to pregnant rats, in the drinking water 2-3 days prior to delivery and the treatment was continued during nursing. Pups were weaned to the same treatment until 6 weeks of age. This treatment decreased levels of taurine in the cerebral cortex by 70%. 4-Aminopyridine was injected intraperitoneally at doses ranging from 4-7 mg/kg. Taurine-deficient rats showed a greater susceptibility to seizures, as demonstrated by a lowered latency for clonic seizures, an increased incidence of tonic seizures and a higher postseizure mortality. These results suggest an involvement of endogenous taurine in nervous excitability.

Effects of monocrotaline pretreatment of rats on removal of 5-hydroxytryptamine and noradrenaline by perfused lung.

1 The alkaloid, monocrotaline, causes significant pulmonary damage in many species, including the rat. We, therefore, determined whether the inactivation of biogenic amines by perfused lungs of rats was modified by prior treatment of the animals with monocrotaline.2 Young rats (45 to 50 g) treated for 21 days with monocrotaline (22 mug/ml) in their drinking water developed right ventricular hypertrophy. Treated animals gained weight more slowly and consumed less food and water than control rats that drank tap water. Lungs from monocrotaline-treated animals were heavier and had a higher protein content than control lungs.3 Isolated lungs from treated animals removed and metabolized 50% less perfused 5-hydroxytryptamine than did controls.4 The diminished 5-hydroxytryptamine metabolism was probably due to impaired delivery of substrate to intrapulmonary monoamine oxidase (MAO) since MAO activity in 600 g supernatant fractions of homogenates of lungs from monocrotaline-treated rats was not different from control values.5 Pulmonary removal of perfused noradrenaline was decreased about 60% by the 21-day treatment, suggesting that the effects of monocrotaline were somewhat nonspecific.6 These effects were not caused by monocrotaline directly, since perfusion of lungs from untreated animals with this drug did not alter removal of co-perfused 5-hydroxytryptamine.7 Reduced pulmonary removal of circulating biogenic amines following pretreatment with monocrotaline may reflect damage to capillary endothelium, which could also affect other metabolic functions of lung.

Effects of taurine and guanidinoethane sulfonate on toxicity of the pyrrolizidine alkaloid monocrotaline.

Monocrotaline (MONO), a pyrrolizidine alkaloid, causes pulmonary arterial hypertension and right ventricular hypertrophy due to hepatic metabolism to the alkylating pyrrole dehydromonocrotaline. Taurine a sulfonic amino acid, is hepato- and cardioprotective in a variety of conditions. We have examined the effects of taurine and its amidino analog, guanidinoethane sulfonate (GES), in rats injected i.p. with MONO (65 mg/kg). Taurine and GES were given as 1% solutions in drinking water beginning 14 days before administration of MONO and continuing for 14 days therafter, when the rats were killed. The MONO group had right ventricular hypertrophy and pulmonary hyperplasia. Compared with control, no significant changes in the right ventricle/left ventricle weight ratio, or the right ventricle/body weight ratio occurred in rats also given taurine of GES. Lung weights in these two groups were higher than in the control group, but below that of the MONO-alone group. The lethality of MONO over 14 days was decreased by taurine (LD50 for MONO alone 80 mg/kg; for MONO + taurine 121 mg/kg). Rats given only MONO had lower hepatic concentrations of GSH and cysteine (Cys), and higher activities of microsomal GSH transferase activity were no different from control. Gamma-Glutamylcysteine (Glu-Cys) synthetase and gamma-glutamyl transpeptidase activities were elevated. In MONO-injected rats given GES, hepatic GSH levels were higher and Cys levels were lower than in either the MONO alone or MONO + taurine groups. Gamma-Glu-Cys synthetase activity was depressed. Microsomal GSH transferase, GSH peroxidase and gamma-glutamyl transpeptidase activities were elevated. Livers of MONO-injected animals showed higher levels of serine (reversed by both taurine and GES) and glycine (Gly; reversed by GES) and lower levels of glutamine. Compared with control rats, the following changes occurred in serum amino acids: MONO alone: increased aspartate, taurine and lysine; taurine-supplemented: increased taurine, methionine (Met) and lysine, and decreased Gly; GES-supplemented: decreased asparagine, serine, Gly, arginine, taurine, and valine. Compared with the MONO-alone group, the taurine-supplemented group had higher glutamate (Glu), Met and alanine, and the GES-supplemented group higher alanine and lower serine, Gly, arginine and valine. We conclude that taurine protects against MONO-induced lethality and right ventricular hypertrophy. GES also protects against right ventricular hypertrophy. However, these agents act by different mechanisms, taurine preventing many of the biochemical changes induced by MONO, with GES inducing additional changes.

Effects of monocrotaline, a pyrrolizidine alkaloid, on glutathione metabolism in the rat.

Monocrotaline (MONO), a pyrrolizidine alkaloid, causes veno-occlusive disease of the liver, pulmonary arterial hypertension, and right ventricular hypertrophy. Toxicity is due to the hepatic formation of a pyrolic metabolite that can be detoxified by conjugation with glutathione (GSH). We have shown that the GSH content of the liver affects the quantity of the pyrrolic metabolite that is released from the liver. We have now examined whether MONO, in turn, affects GSH metabolism. Twenty-four hours after administration of MONO to rats (65 mg/kg, i.p.), the highest concentration of bound pyrrolic metabolites was found in the liver, followed by the lung and kidney. Heart and brain contained lower concentrations of these metabolites. Significantly higher levels of GSH were found in liver and lungs of MONO-treated rats than in saline-injected control animals. In the liver, activities of the following enzymes were elevated: gamma-glutamylcysteine synthetase, GSH synthetase, gamma-glutamyl transpeptidase, dipeptidase, and microsomal GSH transferase. The same changes were seen in the lung. In the heart, gamma-glutamyl transpeptidase activity was decreased markedly, and cytosolic GSH transferase activity was elevated. In the kidney, the activities of GSH synthetase, gamma-glutamyl transpeptidase, and cytosolic GSH transferase were increased. Our results establish a mutual interaction of MONO and sulfur metabolism. It appears that an early metabolic action of MONO is to modify sulfur amino acid metabolism, diverting cysteine metabolism from oxidation to taurine towards synthesis of GSH.

Hepatic metabolism and pulmonary toxicity of monocrotaline using isolated perfused liver and lung.

Monocrotaline is a pyrrolizidine alkaloid obtained from the seeds of Crotalaria spectabilis. When perfused through an isolated liver, monocrotaline is metabolized to Ehrlich reactive (E+) metabolites. Metabolism of monocrotaline was faster in livers from male rats than female rats, was inducible with phenobarbital pretreatment, and was inhibited by coperfusion with the P-450 mixed-function oxidase inhibitor SKF-525A, anoxic perfusion conditions, and low temperatures. When metabolites generated by an isolated liver were perfused through isolated lungs in a recirculatory manner, serotonin transport by the pulmonary endothelium was reduced in correlation with the amount of E+ material contained in the perfusion medium. When metabolism of monocrotaline by the liver was inhibited with SKF-525A, low temperature perfusions or anoxic conditions, serotonin transport by the pulmonary endothelium was unchanged from controls. Monocrotaline alone had no effect on the lung. Thus, isolated perfused livers metabolized monocrotaline to chemical species which produced pulmonary damage in vitro. This provides direct evidence that liver metabolites can cause one of the pneumotoxic effects of monocrotaline observed in vivo.

Differentiation of the cardiac and pulmonary toxicity of monocrotaline, a pyrrolizidine alkaloid.

Monocrotaline, given to rats as a 20 mg/l solution in drinking water for 3 weeks, doubled the mass of the right heart and lung. The rise in lung mass preceded that of the heart. These increases were accompanied by increases in the absolute protein content of the two organs, together with increases in the rates of both protein and RNA syntheses. The increase in lung mass was not accompanied by a change in total collagen content, as measured by two independent methods: 4-hydroxyproline content and detergent fractionation. In contrast, the right ventricle showed more than a 4-fold increase in total collagen content. Total pulmonary lipids increased by 86%, but the lipid: protein ratio was unchanged. Right ventricular lipids were unchanged in amount but the lipid: protein ratio fell by 29%. Lung DNA:RNA ratio decreased 49% and right ventricle DNA:RNA ratio decreased 69%, indicating that both of these organs were responding to monocrotaline with hypertrophy. These results suggest that the processes of hypertrophy differ in the two organs: in the lung, there was no fibrosis despite a marked increase in dry weight, while right ventricular hypertrophy was characterized by increased collagen deposition. There was no alteration in the left ventricle in any of the parameters investigated.

Anti-platelet agents reduce morphological changes of chronic hypoxic pulmonary hypertension.

The pathophysiologic mechanism by which chronic hypoxia causes pulmonary hypertension is unknown. If anti-platelet agents, or other pharmacologic interventions, altered the pulmonary vascular changes induced by hypoxia, information concerning the pathogenesis of the pulmonary hypertension or the potential therapeutic usefulness of the drugs might be obtained. In Study 1, rats exposed to chronic hypobaric hypoxia (PB = 520 mmHg) had a pulmonary arterial medial thickness of 6.7 +/- 0.6 mu compared to 4.1 +/- 0.2 mu* for control, normoxic rats (*p less than 0.05). Administration of dipyridamole (2mg/kg/day), or sulfinpyrazone (11 mg/kg/day) in the drinking water reduced the medial thickness to 5.0 +/- 0.3 mu* and 5.4 +/- 0.5 mu* respectively, thus suggesting the possible involvement of platelets in the response of the media to chronic hypoxia. In Study 2, hypoxic rats treated with the calcium blocker, flunarizine, were found to have less medial hypertrophy than a control group of hypoxic rats. This observation suggests that a decrease in transmembrane calcium flux may also reduce medial hypertrophy.

The transport, biosynthesis and biochemical actions of taurine in a genetic epilepsy.

We have investigated the transport, biosynthesis and turnover of taurine in genetically seizure-susceptible (SS) and seizure-resistant (SR) rats. In SS rats, the rate of taurine uptake into the brain was half the rate in SR rats. As no difference was found in biosynthesis of taurine, these results imply a slower turnover of taurine in SS brain. The effect of taurine on the decarboxylation of glutamate in brain homogenates was determined. In homogenates of SR brains, taurine had no effect but in SS preparations taurine increased the rate of decarboxylation by 20%. Increased decarboxylation of glutamate may be one basis for the prolonged anticonvulsant action of taurine in the SS rat.

Sodium-dependent and sodium-independent binding of taurine to rat brain synaptosomes.

Rat brain synaptosomes (P(2)B fraction) release ?M concentrations of taurine into the incubation medium when incubated at protein concentrations of 0.5-5.0 mg/ml. Repeated incubations, with or without sonication, also induce release of ?M concentration of taurine. When this release is taken into account, two classes of binding sites for taurine can be demonstrated over the intracellular-extracellular concentration range (3 ?M-30 mM) in the presence of 140 mM sodium. The higher affinity class has a K(d) of 25.1 +/- 7.7 ?M (mean +/- SE) and a B(max) of 15.08 +/- 4.27 pmol mg(?1) protein. This site is sodium-dependent, no binding being observed in the absence of sodium. Binding is also suppressed by the taurine transport inhibitor, guanidinoethane sulfonate. We equate this site with the transport site for taurine. The lower affinity site has a K(d) of 33.4 +/- 7.5 mM and a B(max) of 10.3 +/- 1.9 nmol mg(?1) protein. Binding to this site is unaffected by guanidinoethane sulfonate. In the absence of sodium, K(d) and B(max) are decreased to 5.8 +/- 0.56 mM and 2.55 +/- 0.21 nmol mg(?1) protein, respectively. We equate this site with the calcium-modulatory binding of taurine to phospholipid recently demonstrated in cardiac sarcolemma [Huxtable and Sebring, TIPS 7, 481 (1986)].

Phospholipid methylation and taurine content of synaptosomes from cerebral cortex of developing rat.

Changes in taurine concentration and rate of methylation of phosphatidylethanolamine have been examined in rat brain synaptosomes over the course of development. At 7, 14, 21, 28 and 56 days of age, rats were injected i.p. with 300 microCi/kg [3H-methyl]methionine. Synaptosomes (P2B fraction) were isolated from the cerebral cortex 9 h later and incorporation of the methionine methyl group into phospholipid and protein was investigated. Synaptosomal taurine and methionine concentrations were determined at the same ages, as were the concentrations of the major classes of phospholipids (phosphatidylethanolamine, phosphatidylinositol, phosphatidylcholine and phosphatidylserine). Methionine concentration increased between day 7 and 14 and fell thereafter. Phospholipid methylation rates calculated from the specific activity of synaptosomal methionine were high from days 7 and 14 and then fell, whereas protein methionylation increased between day 7 and 28 and then decreased. A strong correlation was found between the taurine concentration of the synaptosome and phospholipid methylation rates during brain development. Protein methionylation rates, however, showed no correlation with taurine concentration.

Seizure-susceptibility and decreased taurine transport in the genetically epileptic rat.

P(2) fractions from brains of genetically seizure-susceptible (SS) rats as compared to seizure-resistant (SR) rats show decreased high affinity uptake of taurine. Uptakes of GABA and glutamate into P(2) fractions did not differ between the substrains. In neonatal SS rats that had never had a seizure, the uptake of taurine is decreased both into the whole brain in vivo and into P(2) fraction in vitro, as compared to age-matched SR rats. This indicates that decreased uptake is not a consequence of seizure activity per se. In non-seizure susceptible progeny of SS rats, the uptake of taurine into P(2) fraction did not differ significantly from that of SR rats. In kidney cortex slices from SS rats, taurine uptake is slightly greater than in slices from SR rats. We propose that the decreased taurine transport in the P(2) fraction of the brains of SS rats may reflect a defect in transport in vivo that contributes to seizure-susceptibility.

The anticonvulsive actions of two lipophilic taurine derivatives.

The taurine derivatives, 2-phthalimidoethanesulfon-N-isopropylamide (taltrimide) and 2-phthalimidoethanesulfonamide (MY-103), were tested intraperitoneally against genetic and experimentally produced seizures. In the genetically seizure-susceptible rat, taltrimide raised the threshold for audiogenic seizures and decreased seizure severity. MY-103 decreased seizure intensity in maximally-responding animals, but was otherwise without effect on sound-induced seizures. Taltrimide had a greater potency against maximal as compared to minimal seizures, and, at 150 mg/kg, it completely suppressed clonic and myoclonic seizures induced by intracerebroventricular injections of guanidinoethane sulfonate (9.2 ?mol) in rats. MY-103, at doses up to 300 mg/kg, was ineffective against guanidinoethane sulfonate-induced seizures. In pentylene tetrazole-induced seizures in the rat, taltrimide (300 mg/kg) raised the threshold for seizures from 80 mg/kg pentylene tetrazole to 115 mg/kg. Taltrimide also raised the threshold for lead-exacerbated pentylene tetrazole-induced seizures. Taurine, being more lipophobic than taltrimide, was ineffective on intraperitoneal administration against pentylene tetrazole-induced seizures. The more lipophilic beta-alanine (8 mmol/kg) raised pentylene tetrazole-seizure threshold on intraperitoneal administration. Thus, lipophilic phthalimido analogs of taurine are effective on peripheral administration against both genetic and experimentally-induced seizures.

Phospholipid composition and taurine content of synaptosomes in developing rat brain.

Synaptosomes (P(2)B fraction) have been isolated from the brains of 1-, 7-, 14-, 21-, 28- and 56-day-old rats. The synaptosomal concentrations of free amino acids and membrane phospholipids were analyzed for these times and expressed as synaptosomal content g(?1) brain. The content of the acidic phospholipids, phosphatidylserine and phosphatidylinositol rose sharply between days 1 and 14, remaining relatively constant thereafter. Sphingomyelin content increased through day 21. The neutral phospholipids, phosphatidylethanolamine and phosphatidylcholine, increased through day 14 and decreased thereafter. The plasmalogen forms of these phospholipids varied similarly. In keeping with the increasing density of synaptosomes in the brain over the first 3 weeks of life, synaptosomal free amino acids increased over this period. Taurine was unique inasmuch as synaptosomal content decreased somewhat between days 14 and 21. Also unique was the strong correlation between taurine concentration of the synaptosomal fraction and the phosphatidylethanolamine: phosphatidylcholine ratio.

In vivo release of neuroactive amines and amino acids from the hippocampus of seizure-resistant and seizure-susceptible rats.

The in vivo release of six radiolabeled amino acids or amines in the hippocampus was investigated in genetically seizure-resistant and seizure-susceptible rats. No differences were found in the spontaneous or high K(+)-evoked efflux of ?-aminobutyric acid, norepinephrine or its metabolites, taurine or ?-aminoisobutyrate. However, seizure-susceptible rats released significantly more d-aspartic acid on K(+)-depolarization. The initial rate of release (flux) was also higher. In view of the ubiquity of synapses in the mammalian brain utilizing excitatory amino acids as their transmitter, we propose that an exaggerated release of these excitants might be a determinant of the innate seizure susceptibility in these animals.

Epilepsy and the concentrations of plasma amino acids in humans.

We have examined the correlation between the presence of epilepsy in humans, and plasma amino acid levels. Subjects were divided into those having pure generalized tonic-clonic seizures (grand mal group), those having generalized tonic-clonic seizures plus other types of epilepsy (mixed group), and those suffering from epilepsies other than grand mal (no grand mal group). Compared to non-epileptic controls, the grand mal group had significantly higher fasting plasma levels of aspartate (100% increase) and glutamate (380% increase) but significant decreases were seen with phenylalanine (?23%), lysine (?27%), and tryptophan (?30%). The no grand mal group showed similar changes except for lysine. The mixed group showed elevations in glutamate, but decreases only in cysteine and methionine. In response to a high protein meal, plasma levels of alanine, cysteine and methionine rose significantly less for the no grand mal group compared to the control group. Increases in aspartate and glutamate concentrations strongly correlated with the prescription of phenytoin. However, the concentrations of these amino acids were not significantly correlated with the actual plasma levels of phenytoin.

Reduction of brain taurine: Effects on neurotoxic and metabolic actions of kainate.

The effects of chronic administration of 2-guanidinoethane sulfonic acid on the levels of intra- and extracellular amino acids in the rat hippocampus were studied. The tissue content of taurine was selectively reduced by almost one third after 9 days of peroral administration of 1% 2-guanidinoethane sulfonate. Extracellular levels of amino acids were monitored with the brain microdialysis method. The taurine concentration in the extracellular fluid was depressed in relation to the decrease in intracellular taurine. Unexpectedly, extracellular (but not intracellular) glutamate was doubled in 2-guanidinoethane sulfonate treated animals. The kainic acid evoked release of taurine was suppressed in the 2-guanidinoethane sulfonate group, whereas the kainate stimulated efflux of glutamate was elevated after 2-guanidinoethane sulfonate administration. The acute metabolic effects of kainate were studied by measuring the efflux of the adenosine triphosphate breakdown products hypoxanthine, xanthine, inosine and adenosine. No differences were found between control and 2-guanidinoethane sulfonate treated rats with respect to basal or kainic acid evoked release of purine catabolites. Also, the neuronal loss caused by kainate injection into the hippocampus was not modified by 2-guanidinoethane sulfonate treatment, suggesting that endogenous taurine does not affect these responses. We conclude that chronic administration of 2-guanidinoethane sulfonate does not sensitize central neurons to the metabolic and toxic actions of kainate.

Actions of guanidinoethane sulfonate on taurine concentration, retinal morphology and seizure threshold in the neonatal rat.

Administration of the taurine transport inhibitor, guanidinoethane sulfonate (GES) to pregnant rats depleted taurine concentrations to approximately one-half of normal values in the newborn progeny. By 5 days of age taurine concentrations had returned to normal in all organs tested with the exception of the lungs. Longer postnatal exposure to GES significantly depressed tissue taurine levels. Prenatal exposure to GES had no effect on fetal development or the capability of the newborn rat to biosynthesize or transport taurine. Pre- and postnatal exposure to GES produced a degeneration of the photoreceptor layer of the retina similar to that observed in cats fed a taurine deficient diet. The pentylene tetrazole chemoshock threshold in GES-treated pups was greater than that in control pups. These results indicate that prenatal exposure to GES deplete taurine concentrations in the newborn rat. Morphological changes are thereby produced in the retina of rat that are similar to those observed in animals having limited ability to synthesize taurine which are maintained on a taurine-free diet.